Suprachoroidal Therapy Shows Promise in Postoperative Macular Edema

Posterior steroid delivery may help resolve persistent subretinal and intraretinal fluid after complex retinal detachment surgery.

By: Matthew Solan, senior writer

Retinal Physician June 23, 2026

Clinical Report: Suprachoroidal Therapy Shows Promise in Postoperative Macular Edema

Overview

A retrospective cohort study indicates that suprachoroidal triamcinolone is associated with greater reductions in retinal fluid and central subfield thickness compared to subtenon triamcinolone and dexamethasone implant therapy in patients with postoperative macular edema following complex retinal detachment repair.

Background

Postoperative macular edema is a common complication following retinal detachment repair, with varying incidence based on surgical complexity and ocular comorbidities. The study highlights the potential of suprachoroidal steroid delivery as a novel therapeutic strategy in this context.

Data Highlights

Treatment	Mean CST Reduction (µm)
Suprachoroidal Triamcinolone	375
Dexamethasone Implant	69
Subtenon Triamcinolone	-75

Key Findings

Suprachoroidal triamcinolone resulted in a mean CST reduction of 375 µm at approximately 6 weeks.
Dexamethasone implants showed a mean CST reduction of 69 µm.
Subtenon triamcinolone treatment led to a mean CST increase of approximately 75 µm.
51% of treated eyes received subtenon triamcinolone, while 46% received suprachoroidal triamcinolone.
Approximately one-quarter of patients required repeat suprachoroidal treatment around three months after the initial injection.
Persistent intraretinal fluid was more likely to necessitate additional interventions.

Clinical Implications

The findings suggest that suprachoroidal triamcinolone may be a more effective option for managing postoperative macular edema in complex retinal detachment cases. Clinicians should consider this approach for patients who do not respond adequately to traditional steroid therapies.

Conclusion

Suprachoroidal therapy shows promise in effectively reducing postoperative macular edema, warranting further investigation and consideration in clinical practice.

PentaVision

Retinal Physician